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Abstract
Background: The liver stages of malaria parasites are inhibited by cytokines such as interferon-c or Interleukin (IL)-6. Binding
of these cytokines to their receptors at the surface of the infected hepatocytes leads to the production of nitric oxide (NO)
and radical oxygen intermediates (ROI), which kill hepatic parasites. However, conflicting results were obtained with TNF-a
possibly because of differences in the models used. We have reassessed the role of TNF-a in the different cellular systems
used to study the Plasmodium pre-erythrocytic stages.
Methods and Findings: Human or mouse TNF-a were tested against human and rodent malaria parasites grown in vitro in
human or rodent primary hepatocytes, or in hepatoma cell lines. Our data demonstrated that TNF-a treatment prevents the
development of malaria pre-erythrocytic stages. This inhibitory effect however varies with the infecting parasite species and
with the nature and origin of the cytokine and hepatocytes. Inhibition was only observed for all parasite species tested
when hepatocytes were pre-incubated 24 or 48 hrs before infection and activity was directed only against early hepatic
parasite. We further showed that TNF-a inhibition was mediated by a soluble factor present in the supernatant of TNF-a
stimulated hepatocytes but it was not related to NO or ROI. Treatment TNF-a prevents the development of human and
rodent malaria pre-erythrocytic stages through the activity of a mediator that remains to be identified.
Conclusions: Treatment TNF-a prevents the development of human and rodent malaria pre-erythrocytic stages through the
activity of a mediator that remains to be identified. However, the nature of the cytokine-host cell-parasite combination must
be carefully considered for extrapolation to the human infection.
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Introduction
Tumour necrosis factor (TNF)-a is a cytokine with pleiotropic
effects including anti-microbial activities [1]. In malaria infections,
it has been shown that TNF-a could have both beneficial and
detrimental effects. TNF-a is detected in the circulation during the
erythrocytic phase of the infection in humans [1–3] and in mice
[4,5]). In both hosts, high levels of this cytokine have been
associated with malarial pathology such as fever [6], and cerebral
malaria [3,5]. On the other hand, TNF-a has also been shown
to have a potent anti-parasitic activity. Administration of
recombinant TNF-a protected against blood stage infection with
Plasmodium chabaudi in mice [7], while mice deficient for TNF-a
controlled P. chabaudi adami blood infections less efficiently [8]. In
humans, sustained high levels of TNF-a were associated with rapid
clearance of fever and parasites [9]. There are controversial
observations concerning the role of TNF-a against the pre-
erythrocytic (PE) stages of the malarial infection. Schofield et al.
reported that recombinant human TNF-a directly inhibited P.
berghei grown in vitro in the HepG2 human hepatoma cell line, and
in vivo in rats and mice [10]. However, we have previously found
that P. yoelii parasites grown in cultured purified mouse primary
hepatocytes were unaffected by TNF-a, whereas this cytokine
inhibited the hepatic development of this parasite in vivo [11]. We
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17464then showed for this rodent malaria model that the inhibitory
effect observed in vivo was actually mediated by the IL-6 secreted
by non-parenchymal liver cells in response to TNF-a stimulation
[11]. Thus depending on the host/parasite combination, different
effects of TNF-a on PE parasites were reported. In this study, we
wished to reassess the role of some of the biological and
experimental parameters on the inhibition of Plasmodium hepatic
stages observed in in vitro assays of TNF-a activity.
Materials and Methods
Ethics
Allexperimentsandprocedures involvingmicewereapproved by
the ‘‘Direction De ´partementale des Service Ve ´te ´rinaires de Paris,
France’’ (Authorisation No 75–129) and performed in compliance
with regulations of the French Ministry of Agriculture for animal
experimentation (1987). Human liver fragments used to prepare
primary hepatocyte cultures were collected after written informed
consent from patients undergoing a partial hepatectomy. The
collection and use of these tissues were undertaken in accordance
withFrenchnational ethical regulations and have been approved by
the Ethic Committee of the Centre Hospitalo-Universitaire Pitie ´-
Salpe ˆtrie `re, Assistance Publique-Ho ˆpitaux de Paris, Paris, France.
Cytokines and chemicals
Different batches of human and murine TNF-a with similar
specific activity were obtained from R&D systems. Endotoxin
levels in the different batches used in this study were always below
1.0 EU per 1 mg as reported by the manufacturer. S-methyl-
thiourea (SMT, Sigma), a potent inhibitor of iNOS [12] and N-
acetyl-cysteine (NAC), which prevents oxygen free radical [13],
were obtained from Sigma.
Mice and parasites
BALB/cJ mice were purchased from Harlan Laboratories
(Gannat, France), and were housed in a pathogen-free rodent
barrier facility. Sporozoites of the uncloned line of Plasmodium yoelii
yoelii 265BY strain (Pyy265BY), of P. yoelii yoelii 17X strain clone
1.1 (Py17X), and of P. berghei ANKA cloned line transfected with
GFP (PbA) [14] were obtained from infected salivary glands of
Anopheles stephensi mosquitoes, 16 to 21 days after an infective
mouse blood meal. After aseptic dissection, salivary glands were
homogenized in a glass grinder and diluted in culture medium
[15]. Sporozoites of the NF54 strain of Plasmodium falciparum were
obtained from infected salivary glands of A. gambiae mosquitoes
which have been fed two weeks before on infected human blood
cultures using a membrane-based feeder system [16]. After aseptic
dissection, salivary glands were disrupted by trituration in a glass
tissue grinder, diluted in culture medium and the sporozoites were
counted using a KovaSlideH chamber.
Cells
Mouse hepatoma cells Hepa1–6 (ATCC CRL-1830) (10
5 per
well), were cultured inDMEM(Invitrogen) supplemented with 10%
FCS (Invitrogen), 2 mM glutamine, 1% penicillin-streptomycin of a
100 X stock solution (Invitrogen). Human hepatocarcinoma cells
HepG2/CD81+ (HepG2 stably expressing CD81) (10
5 per well)
[17] were cultured in supplemented DMEM as above, in culture
dishes coated with rat tail collagen I (Becton Dickinson. Mouse
primary hepatocytes were prepared as described, with minor
modifications [18]. Cells were isolated by collagenase perfusion
(Boehringer Mannheim)ofliverfragmentsandwerefurther purified
overa 60%Percollgradient (PharmaciaBiotech,Uppsala, Sweden).
Mouse hepatocyte purity and viability were .95% as assessed by
Trypan blue dye exclusion. Human primary hepatocyte cultures
were prepared as described with minor modifications [19]. Briefly,
cells were isolated by collagenase (Roche) perfusion of human liver
fragments, which were collected and used in agreement with the
French ethical regulations, and were further purified over a 40%
Percoll gradient. Human hepatocyte purity and viability were
.99% as assessed by Trypan blue dye exclusion. Mouse and
human hepatocytes were seeded in eight-chamber plastic Lab-Tek
slides (Nunc) coated with rat tail collagen I (Becton Dickinson) at a
density of 1610
5 cells per well for primary murine hepatocytes, and
of 2610
5 cells per well for primary human hepatocytes cells, and
cultured at 37uC, 5% CO2, in DMEM medium as above
supplemented with 10
27 M dexamethasone (Sigma) after complete
cell adherence (12–24 hours).
Evaluation of TNF-a cytotoxicity
Toxicity of the cytokine to primary culture of hepatocytes or
hepatoma cell lines in flat-bottom 96 wells (20610
3 cells/well) was
evaluated using a methylthiazolyldiphenyl-tetrazolium bromide
(MTT) assay. Briefly, cytokines were added in triplicate at
decreasing concentrations. Medium was replaced 3 hours after
sporozoite infection and every day thereafter up to day 4 (for rodent
parasites) or 7 (for P. falciparum) with fresh medium containing the
cytokine at the same concentration. Twenty-four hours after the last
medium change, 110 ml of a solution containing 10 mlo fM T T
(Sigma) solution (5 mg/ml) and 100 ml of medium were added and
the cultures incubated for a further 4 hours. The formazan crystals
that were formed were dissolved using 100 ml of a 1:1 DMSO:
ethanol solution. Optical density was read immediately at 570 nm
with a reference wavelength at 630 nm [20].
In vitro assay of sporozoite invasion of and development
in hepatocytes and HepG2 cells
After removal of medium from the culture chambers, ten
thousands sporozoites were added in 100 ml of fresh supplemented
medium with various quantities of TNF-a tested, and at different
times during cultivation. Medium was replaced at 22 4 ,0 ,3 ,a n d
24 h after rodent malaria sporozoite inoculation, and at 224, 0, 3,
24 h and then every day up to day 5 after P. falciparum sporozoite
inoculation of primary human hepatocytes with fresh medium
containing or not the cytokine. In one experiment, supernatant was
collected from wells containing human hepatocytes treated with
TNF-a (100 ng/m) of for 2 days. Plasmodium sporozoites (10
4 in a
50 ml) were added to this supernatant (50 ml) or to fresh medium
(50 ml). The final solution (100 ml) containing the sporozoite was
added to the culture. Medium was replaced after 3 h, 24 h, and then
every day up to day 5 after sporozoite inoculation. Experimental
determination of the number of liver stage parasites was performed in
triplicate or quadruplicate. Cultures were stopped 48 h (for rodent
malaria species) or 5 days (for P. falciparum) after sporozoite infection,
fixed with cold methanol and schizont numbers were assessed by
immunofluorescence using antibodies recognizing Plasmodium liver
stages as previously described [21,22] and were quantified by
microscopic examination or using the Odyssey infra red imaging
system (Li-COR Biosciences) [23]. Percentage of inhibition of the
development is calculated by comparing the numbers of parasitic
forms in the experimental wells versus control wells.
Results
Effect of human TNF-a on HepG2-CD81 cells infected
with murine Plasmodium species
HepG2 is a hepatoma cell line easily propagated in vitro [24] that
has been shown to sustain the development of the P. berghei [25]
TNF-a and Malaria-Pre-Erythrocytic Stage
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showed that HepG2 cells transduced with CD81 are thereby made
permissive to P. yoelii development, providing a good system to
study P. yoelii liver stage biology, thus reducing the need for the
more tedious primary murine hepatocyte cultures. We employed
this cell line to assess the role of TNF-a against the hepatic stages
of malaria parasites.
When human TNF-a was added to HepG2-CD81 cultures over
a four-day period centred on the time of sporozoite inoculation,
Pyy265BY hepatic parasite development was inhibited in a dose
dependent manner (Figure 1A). Significant inhibition was
observed even at a low dose of 10 ng/ml. Only minor increases
in the level of inhibition were obtained at doses above 100 ng/ml
(Figure 1A). We then tested the influence of the timing of TNF-a
Figure 1. Human TNF-a inhibits the pre-erythrocytic stage of Pyy265BY. A. HepG2/CD81 hepatoma cell cultures were treated with various
concentrations of recombinant human TNF-a, 48 h prior to, at the time of, and then 3 h and 24 h after sporozoite inoculation. Cultures were stopped
45 h after infection. Data are presented as the mean (6 SD) reduction in Pyy265 liver schizonts numbers and represent data from two independent
experiments (one represented by filled circles and the other by open circles). Parasite number reduction was calculated by enumerating 48 h liver
schizonts in triplicate cultures exposed or not to TNF-a. Data are presented as the mean (6 SD) reduction in liver schizont numbers in triplicate wells
compared to the mean number in 6 control wells. The number of liver schizonts in control wells was 6769.9. B. Timing of the antiparasitic effect of
human TNF-a. HepG2/CD81 cells were incubated with 100 ng/ml of human TNF-a for different times. Cultures were stopped 48 h after sporozoite
inoculation. Data are presented as the mean (6 SD) numbers of liver schizonts in triplicate experimental wells and in six control wells. * p,0.05 versus
control non-treated cultures (Kruskal-Wallis test, followed by Dunn test). The rate of infection Pyy265 sporozoites for HepG2/CD81 hepatoma cell was
between 0.5 to 2% depending on the experiment. Data are representative of three independent experiments with similar results.
doi:10.1371/journal.pone.0017464.g001
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cultures where the cytokine was added only 1 day before
sporozoite inoculation were also significantly inhibited by
100 ng/ml of TNF-a (Figure 1B). However, no inhibition of
parasite development could be observed when TNF-a was first
added starting at the time of sporozoite inoculation or thereafter
(Figure 1B). The inhibitory activity of TNF-a was specific to the
parasites because TNF-a had no cytotoxic effect on infected or
normal HepG2 cells as measured by the MTT assay, even when
added at the highest doses used. Indeed, the optical density values
obtained in wells containing untreated cells [(0.95360.2 arbitrary
units (A.U.)] or cells treated for 4 days with 100 ng/ml TNF-a and
infected with P. yoelii sporozoites (1.2960.0.05 A.U.) did not differ
significantly.
We next tested the effect of human TNF-a on PbA parasites,
thus providing a reasonable comparison with the study of
Schofield et al. where an inhibitory effect of human TNF-a against
P. berghei NK65 strain was reported [10]. When human TNF-a at
an inhibiting dose of 100 ng/ml was added to HepG2-CD81
cultures starting 48 h before sporozoite inoculation and over a
four-day period until the end of the parasite cultivation period
48 h thereafter, PbA liver stage development was also inhibited in
a dose dependent manner (Figure 2), though the magnitude of the
inhibition was lesser than that observed for Pyy265BY.
Effect of TNF-a on mouse hepatoma cell line Hepa 1–6
and primary mouse hepatocytes infected with murine
Plasmodium species
In order to test whether the findings obtained using HepG2-
CD81 cells can be extended to other host cell/parasite
combinations, we repeated the TNF-a treatment (100 ng/ml
initiated at 48 h before sporozoite inoculation and maintained for
the subsequent 48 h) with mouse hepatoma cells Hepa 1–6 and
primary cultures of purified mouse hepatocytes, both of which
sustain the growth of Plasmodium species that infect rodents [18,27].
Mouse TNFa significantly inhibited PbA in Hepa1-6 cells
(Figure 3A) or in primary hepatocyte cultures (Figure 3B), whereas
Figure 2. Human TNF-a inhibits the pre-erythrocytic stage of
PbA. HepG2/CD81 hepatoma cell cultures were treated with various
concentrations of recombinant human TNF-a, 48 h prior to, at the time
of, and then 3 h and 24 h after sporozoite inoculation. Cultures were
stopped 48 h after sporozoite inoculation. Data are presented as the
mean (6 SD) reduction in 48 h PbA liver schizont numbers from
triplicate experimental wells compared to those from 8 control wells.
The number of liver schizonts in the control wells was 357631.
* p,0.05 versus control non-treated cultures (Kruskal-Wallis test,
followed by Dunn test). The rate of infection PbA sporozoites for
HepG2/CD81 hepatoma cell was between 0.3 to 2% depending on the
experiment. Data are representative of two independent experiments
with similar results.
doi:10.1371/journal.pone.0017464.g002
Figure 3. Effect of human or mouse TNF-a against the pre-erythrocytic stage of PbA and Pyy265BY grown in Hepa 1–6 hepatoma
cells or primary hepatocytes cultures. (A) Hepa 1–6 cells and (B) primary hepatocyte cultures were treated with 100 ng/ml of recombinant
human or mouse TNF-a, 48 h prior to, at the time of, and then 3 h and 24 h after sporozoite inoculation. Cultures were stopped 48 h later. Data are
presented as the mean (6 SD) reduction in PbA liver schizont numbers at 48 h in triplicate experimental wells as compared to those enumerated in 6
control wells. In the control wells, there were 110.3613.1 liver schizonts in Hepa1-6 and 602683.4 in the primary mouse hepatocytes infected with
PbA, and 25.563.6 liver schizonts in Hepa1-6 and 443.56133.5 in primary hepatocytes infected with Pyy265 BY. * p,0.05 versus control non-treated
cultures (Kruskal-Wallis test, followed by Dunn test). The rate of infection for Pyy265 sporozoites was 0.02-.004% for Hepa1.6 cells and 0.1–2% for
primary mouse hepatocytes. For PbA sporozoites, it was of 0.1–0.5% for Hepa1.6 cells and 0.5–1% for primary mouse hepatocytes. Data are
representative of two independent experiments with similar results. ND, not done.
doi:10.1371/journal.pone.0017464.g003
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cytes (Figure 3).
We next tested the effect of human TNF-a on mouse cells since
it was shown previously that in vivo treatment with this cytokine
inhibited P. berghei NK65 liver stage development [10]. However,
human TNF-a may have an indirect inhibitory effect on the liver
stage in situ, for e.g. by inducing the production of another anti-
liver stage cytokine such as IL-6 by nonparenchymal liver cells.
We wished to ascertain whether the inhibition noted above was
due to direct interaction with hepatocytes [11]. The liver stage
development of parasites (Pyy265BY or PbA) grown in primary
mouse hepatocytes was not inhibited by treatment with human
TNF-a (Figure 3B). These results indicate that parasite species are
differentially susceptible to the inhibitory activity of TNF-a, and
that this is influenced by the origin of the TNF-a as well as the
type and origin of the host cells in which the parasites develop. It is
worth noting that treatment with TNF-a had no cytotoxic effect
on infected or non-infected primary mouse cells as measured by
the MTT assay. The difference in the optical density values
obtained for wells containing untreated cells (0.4760.09 A.U.) or
cells treated for 4 days with 100 ng/ml TNF-a and infected with
P. yoelii sporozoites (0.4160.05 A.U.) were not significant.
Effect of TNF-a on primary human hepatocytes infected
with P. falciparum
We then tested the effect of TNF-a on the development of P.
falciparum in human primary hepatocytes, a host/parasite combi-
nation of direct clinical relevance. We used highly purified human
hepatocytes to prevent indirect effect of TNF-a on contaminating
nonparenchymal cells as shown previously [11]. P. falciparum liver
stage development was inhibited when the cultures were treated
with human TNF-a at 100 ng/ml, but not 1 ng/ml, 24 h or 48 h
prior to sporozoite inoculation and until day 5 thereafter (Figure 4).
Inhibition was more pronounced when the hepatocytes were pre-
incubated with human TNF-a 48 h as compared to 24 h before
sporozoite inoculation. As for the other hepatocyte cells, treatment
with TNF-a had no cytotoxic effect on primary human
hepatocytes as measured by the MTT assay. The optical density
values obtained for wells containing untreated cells (0.7860.005
A.U.) or cells treated with for 4 days with 100 ng/ml TNF-a and
infected with P. yoelii sporozoites (0.79360.03 A.U.) did not differ
significantly.
Absence of effect of nitric oxide derivatives and radical
oxygen intermediates inhibitors on TNF-a mediated pre-
erythrocytic stage inhibition
In order to determine how TNF-a inhibits liver stage parasite
development, we used inhibitors that block the NO or the ROI
pathways, both of which have been implicated previously in PE
killing. First, we used S-methyl-thiourea (SMT), a competitive
inhibitor of the inducible nitric oxide synthase [12]. Addition of
SMT to cultures treated with 100 ng/ml of human TNF-a did
not reverse the effect of the cytokine against Pyy265BY HepG2/
CD81 (Figure 5A) or against P. falciparum in primary human
hepatocytes (Figure 6A). We next tested whether inhibition was
mediated via the ROI pathway by using N-acetyl-cysteine (NAC),
the precursor of glutathione and a potent endogenous antioxidant
[13]. Addition of NAC did not reverse TNF-a mediated
inhibition of Pyy265BY in HepG2/CD81 (Figure 5B), or that
of P. falciparum in primary human hepatocytes (Figure 6A). We
also observed that SMT and NAC did not reverse the inhibitory
effect of TNF-a on PbA-infected HepG2-CD81 hepatoma cells
(data not shown).
A soluble mediator synthesized by human TNF-a-
stimulated human hepatocytes prevents P. falciparum
development
Since inhibition was observed only when cells were treated 48 h or
24 h before sporozoite infection but not on the time of sporozoite
inoculation, we hypothesized that TNF-a-treated hepatocytes might
release a parasite-inhibitory soluble mediator as previously shown for
IL-1 or other inflammatorystimuli [28,29]. P.falciparumsporozoitesin
normal medium were added to supernatant medium obtained from
human hepatocytes treated for 48 h with TNF-a (1/1 volume). The
mixture was then added to fresh human hepatocytes to initiate the
infection. A strong significant inhibition of sporozoite development
was observed, and it reached levels similar to those induced by direct
TNF-a pre-treatment of the cultures (Figure 6B). This showed that an
inhibitory soluble mediator was produced by TNF-a-stimulated
hepatocytes.
Discussion
The in vitro experiments presented here were designed to assess
parameters, such as the origin of the cytokine, the origin of the
Figure 4. Human TNF-a inhibits the pre-erythrocytic stage of P.
falciparum. Primary human hepatocyte cell cultures were treated with
various concentrations of recombinant human TNF-a, 24 h (A) or 48 h
(B) before, at the time of sporozoite inoculation, and then every day for
day 1 to day 5. Cultures were stopped 5 days later after sporozoite
inoculation. The data presented are mean numbers (6 SD) of 5 days P.
falciparum liver stages from triplicate experimental wells and from 8
control wells. * p,0.05 versus control non-treated cultures (Kruskal-
Wallis test, followed by Dunn test). The rate of infection for P. falciparum
sporozoites was 0.2–0.5% for primary human hepatocytes depending
on the experiment. Data are representative of two independent
experiments with similar results.
doi:10.1371/journal.pone.0017464.g004
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might affect the anti-liver stage activity of TNF-a. Different types
of hepatocytes and hepatoma cell lines together with 3 Plasmodium
species were used. Our main finding is that human TNF-a was
able to inhibit the hepatic development of two rodent malaria
species, P. yoelii and to a lesser extent P. berghei (Figure 1), and most
importantly that of P. falciparum (Figure 4). We showed that this
activity of TNF-a was dependent on the host cell type and on the
schedule of this cytokine’s administration. Maximal inhibition
could be obtained when human TNF-a was administered 48 h
before sporozoite inoculation to HepG2-CD81 cells (Figure 1).
Significant inhibition was still observed when cells were treated
24 h before sporozoite inoculation both in HepG2-CD81 infected
with P. yoelii and in highly purified primary human hepatocytes
infected with P. falciparum. The good concordance between the
data derived from P. yoelii/HepG2-CD81 combination and that
from the P. falciparum/human primary hepatocyte combination
makes it a good surrogate in future studies of the role of non-
specific immune components against the malaria hepatic stages.
These results differed from those obtained using primary mouse
hepatocytes where an effect was observed only when the cultures
were treated 48 h (Figure 3) but not 24 h [11] before P. yoelii
sporozoite inoculation. Of the different parameters that might
account for this difference we favour those related to the TNF-
amechanism of action. Murine TNF-a and human TNF-a differ
in their affinity to the various host TNF receptors. Human TNF-a
signals only through TNFR1 in mouse cells [30] and, as shown
here, it had no effect on primary mouse hepatocytes infected with
P. yoelii or with P. berghei (Figure 3). Signalling by TNF-R1 signals is
effected through the TRAD/NEMO pathway to NF-kB or
through FAD to activate caspase for apoptosis. TNF-R2 also
mediates NF-kB activation through the TRAF pathway [31],
however, in hepatocytes only TNFR1 mediates activation of NF-
kB [32]. The NF-kB pathway is necessary for the induction of the
NO or ROI in hepatocytes [33]. These two mediators have been
shown to inhibit the Plasmodium liver stage [34,35]. We did not
observe the induction or NO and ROI, which strongly suggests
that it was TNFR2 but not TNFR1 that was involved in TNF-a
signalling in infected hepatocytes. It has been proposed recently
that malaria parasites manipulate their host hepatocytes to make
them resistant to the apoptosis induced by TNF-a in vivo or in vitro
[36] through interference with the NF-kB pathway [37] and
consequently allowing them to escape the TNFR1-signaled
cytotoxic effect of TNF-a. In addition, since signalling through
TNF-R2 has also been involved in the necrotic effect of TNF-a
Figure 6. A soluble mediator but not NO or RO intermediates
synthesized by human TNF-a-stimulated human hepatocytes
inhibits P. falciparum development. A. Primary human hepatocytes
were treated or not with 100 ng/ml of human TNF-a together with or
without SMT or NAC at 48 h before, at the time and every day for day 1
to day 5 after sporozoite inoculation. B. In the same experiment,
supernatants from cells treated previously for 48 h with human TNF-a
were added together with P. falciparum sporozoites to fresh human
primary hepatocytes. Medium was changed after 3 hr and every day
after sporozoite inoculation. In both experimental settings, cultures
were stopped 5 days later. Data are presented are the mean (6 SD)
reduction in liver schizont numbers in triplicate wells to the mean
number in 6 control wells and are derived from one of two experiments.
The numbers of P. falciparum 5 day-liver schizonts in the 6 control wells
were 179.2626.1. * p,0.05 versus control non-treated cultures (Kruskal-
Wallis test, followed by Dunn test).
doi:10.1371/journal.pone.0017464.g006
Figure 5. The effect of human TNF-a against Pyy265BY is not
mediated by NO or ROI. HepG2/CD81 hepatoma cells treated or not
with 100 ng/ml of human TNF-a together with or without SMT (A) or
NAC (B) 48 h before, at the time of, and then 3 h and 24 h after
sporozoite inoculation. Cultures were stopped 48 h later. Data are
presented as the mean (6 SD) reduction in liver schizont numbers in
triplicate wells compared to the mean number in 6 control wells. The
numbers of Pyy265BY liver schizonts in the 6 control wells were
145.569 (A), and 14869 (B). The results are representative of three
independent experiments. * p,0.05 versus control non-treated cultures
(Kruskal-Wallis test, followed by Dunn test).
doi:10.1371/journal.pone.0017464.g005
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hepatocyte necrosis. Such an effect was ruled out because cell
cytotoxicity was not observed in the MTT assays conducted after
treatment with TNF-a.
The fact that the inhibitory effect of TNF-a was observed only
when cultures were pre-incubated with the cytokine suggested that
stimulated hepatocytes secrete an inhibitory factor and/or that the
TNF-a treatment makes them refractory to infection. Host cell
refractoriness is unlikely because addition of the supernatant from
TNF-a-stimulated hepatocytes to the cultures was sufficient to
obtain hepatic parasite inhibition. TNF-a alone or together with
IL-6 and IL-1, is known to induce the synthesis of acute phase
response proteins by hepatocytes. Although the acute phase
response to inflammatory stimuli is evolutionary conserved,
species-specific differences exist [39,40]. IL-1 was previously
shown to prevent sporozoite development in human or rat
primary hepatocytes in vitro through the action of an acute phase
protein, the C-reactive protein (CRP) [11,29]. Human or rat C-
reactive proteins can bind sporozoite and prevent their invasion
and further development in hepatocytes [12,30]. However, Yap
et al. [41] have shown that CRP is not produced by human
hepatocytes after TNF-a stimulation. They also showed that TNF-
a treatment blocks the induction of CRP stimulated by IL-1 or IL-
6 treatment of human hepatocytes. This suggest strongly that this
acute phase protein does not mediate the TNF-a effect. It has been
reported previously that two other acute phase proteins, the
protease inhibitors a1-antitrypsin and a2 macroglobulin, were also
able to prevent sporozoite infection and development [42].
Parasite proteases are necessary for sporozoite invasion in
hepatocytes [43] and thus may be targeted by these two protease
inhibitors. However, although TNF-a has been shown to increase
the synthesis of a1-antitrypsin [44] or a2 macroglobulin [45] in
HepG2 cells, it does not induce these molecules in human
hepatocytes [40]. Thus, the nature of the inhibitory mediator
secreted by human hepatocytes is still unknown and deserves
further study. In the mouse liver the profile of acute phase proteins
induced by inflammatory stimuli is different, for example mouse
hepatocytes do not synthesize CRP. Serum Amyloid A is induced
by TNF-a in mouse hepatocytes [46] and it might be responsible
for the inhibition that is consequent to TNF-a-stimulation of
mouse primary hepatocytes or mouse hepatoma cell lines.
However, Serum Amyloid A is not induced in human hepatocytes
by TNF-a stimulation [47] suggesting that other mediators might
be involved.
During malaria blood stage infection, the production of TNF-a
is increased [1,3], and these cytokine might modulate new liver
stage infections [48,49]. By extension, any systemic inflammations
or infections or more localized liver infections, of viral or bacterial
origin, that induces high level of TNF-a might also have an
inhibitory effect on the liver stages, which could consequently
influence the outcome of a subsequent blood infection and its
associated pathology [48,49].
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